Page 172 - CW E-Magazine (30-4-2024)

News from Abroad PCHi CHINA 2024

PARTNERSHIP SOURCING PLATFORM
As ahi Kasei & Axolabs to advance oligonucleotide PCHi expo showcases growing sophistication

therapeutics development of Chinese cosmetics ingredients market

A sahi Kasei Bioprocess (AKB), he 2024 edition of PCHi (Per-
part of Japan’s Asahi Kasei Group, sonal Care and Home Ingredi-
and Germany’s Axolabs have Tents) exhibition, held in Shanghai
announced a partnership in the fi eld from March 20 to 22, underscored
of oligonucleotide therapeutics. the rapid progress being made by the
Chinese cosmetics ingredients market,
The fi rms will collaborate to build post COVID, especially in areas of
a cutting-edge oligonucleotide cGMP research-intense offerings. The pre-
manufacturing facility spanning an dominantly Chinese suppliers-focussed
area of 59,000 square feet in Berlin. trade fair witnessed a highly confi dent
This cooperation aims to accelerate the domestic industry competing with
development and commercialisation global majors in new product launches
of oligonucleotide-based therapies. and showcasing innovative solutions.
Operations at the newly built facility
are planned to commence in late 2024. The show, which is now recognised
as the leading sourcing platform for
Oligonucleotide therapies offer well as their delivery mechanisms. is establishing a new GMP manufac- Chinese personal & home care ingre-
a targeted approach to modulating Currently, a total of 25 approved turing hub in Berlin. By utilising the dients, also saw increased international
gene expression, splicing, and pro- oligonucleotide therapeutics have been expertise of Asahi Kasei Bioprocess, interest. The organiser, Reed Sino-
tein production. By selectively mani- approved by regulatory authorities specialising in the fi eld of oligosyn- pharm Exhibitions (RSE), touted the
pulating specifi c molecular process- worldwide, and numerous others are thesis equipment, and Axolabs, the key statistics to affi rm PCHi’s global
es, these therapies hold the potential in pre-clinical and clinical studies facility will serve as a pivotal resource to reach and infl uence: participation of
to treat a wide range of diseases (e.g., with promising prospects for further expedite therapeutic breakthroughs in almost 800 exhibitors from over 27
genetic disorders, cancer, and certain development. the industry. It is designed to accom- countries & regions; and around 30,000
viral infections) at the genetic level, modate a wide range of production visitors, including international visitors
providing new treatment options for To meet the growing demand for scales (small to large/commercial) and from over 70 countries & regions.
patients. In recent years, remarkable oligonucleotide therapeutics, Axolabs, will benefi t from AKB’s suite of oligo
advancements in nucleic acid chemistry a Contract Research Development & manufacturing equipment – covering “PCHi provides cosmetics, home
and cell biology have contributed Manufacturing Organisation (CRDMO) all upstream and downstream manu- and personal care manufacturers, ingre-
to refi ning the design and optimisa- providing drug substances for facturing unit operations from synthe- dients suppliers, cosmetics packaging,
tion of oligonucleotide therapies, as oligonucleotide-based therapeutics, sis to concentration. machinery and product testing provi-
ders from all over the world with a qua-
HEALTHCARE lity platform for ingredients sourcing,
Brenntag inks distribution deal with Taiwan’s Greenyn gaining insight into global trends, and
networking with experts,” RSE said.
Biotechnology
Among the key highlights of the ‘New Products Showcase’, ‘Beauté
Brenntag, the German chemicals vegetable extract. “We are excited to in product development and marketing show were the product launches – in- Gourmet’, and ‘Sustainability Zone’.
and ingredients distributor, has inked a announce our strategic collaboration with and with Brenntag’s extensive distri- cluding some worldwide debuts – of The ‘New Technology Sessions’ also
distribution agreement with Taiwanese Brenntag to serve the surge in the con- bution network, we can cater to evolving novel ingredients by leading global featured select exhibitors with their
dietary supplements specialist, Greenyn sumption of complementary medicine consumer preferences with innovative players like Givaudan, Lucas Meyer latest offerings.
Biotechnology, covering a range of solu- as consumers in the Asia Pacifi c priori- formulations, personalised supplements, Cosmetics, and Provital, as well as
tions such as Insumate bitter melon pep- tise holistic approaches to health and and tailored health solutions,” said Chinese fi rms. Other novel innova- The ‘PCHi Annual Industry Confe-
tides, Antromax Antrodia Cinnamomea well-being. By leveraging the combined Mr. Chia-Fen Wu, Chairman, Greenyn tions and technologies were showcased rence 2024’ – organised alongside the
and Zymologist fermented fruit and prowess of both companies’ strengths Biotechnology. across the event’s feature areas like the exhibition – featured more than 200

172 Chemical Weekly April 30, 2024 Chemical Weekly April 30, 2024 173

Contents Index to Advertisers Index to Products Advertised